Our Services
Policy & Government Risk Decisions
We are engaged when policy determines revenue, access, or survival.
We translate EU, German Federal Ministry of Health, and Chinese healthcare policy into clear commercial consequences for boards and executive teams.
Typical outcomes
-
Pricing and reimbursement feasibility
-
Procurement and tender risk
-
Government positioning that protects market access
Market Entry
Market Entry Go / No-Go Decisions (EU ↔ China ↔ US)
We answer one question:
Should you enter this market - or not?
We assess regulatory clearance, reimbursement reality, procurement logic, and partner risk before capital is committed.
Deliverable
-
Go / No-Go market entry decision
-
Partner and location risk ranking
-
Timeline and gating factors
Digital Execution Under Regulation
Digital health fails when policy, reimbursement, and procurement are ignored.
We execute only where scaling is realistic, aligning AI, data, and digital platforms with regulatory and reimbursement constraints in Europe and China.
Used for
-
Pharma digital programs
-
AI-enabled care models
-
Hospital systems
Output
Execution blueprint with go / stop thresholds.
What Our Clients Say
”The expertise of SILREAL provided a multi-layered view of the current developments in China and thus enriched the discussion on future digitalized healthcare in Germany. His contribution was found to be extremely valuable by all participants.”
Ingo Behnel
Director General European and International Policy Issues
German Federal Ministry of Health
"I compliment SILREAL for their high level of entrepreneurship and competency which helped us successfully realize an innovative bilateral exchange between German and China officials and expert groups. SILREAL’s team has been a delight to work with: reliable, goal-oriented, creative, in the details while never losing track of the big picture."
Stefan Werner Weber
Vice President, Global Policy
AstraZeneca
"Bayer supported the Sino-European Digital Health Summit 2019 in Berlin. With over 100 participants from the healthcare sector, the goal was to better understand new technologies for healthcare and develop cooperation opportunities between Europe and China. SILREAL led the Summit and made it a great success. His networks made it possible to bring decision makers together for an exciting and productive exchange with high quality.”
Dr. Alexander Krupp
Vice President, Clinical Product
Bayer
Trusted By
Why Boards and Executives Engage SILREAL
We De-Risk Cross-Border Decisions
Most failures in EU-China-US healthcare expansion are not technical - they are political, regulatory, and institutional.
We identify where decisions break before capital, reputation, or time is committed.
What this means in practice
-
Clear go / no-go thresholds
-
Early red-flag detection
-
Fewer “strategic surprises” post-entry
We Operate Inside Policy Reality - Not Slides
We work at the interface of:
-
Government decision logic
-
Regulatory constraints
-
Commercial execution
Our work reflects how decisions are actually made inside ministries, payers, and public systems - not how they are presented externally.
Result
Strategies that survive contact with regulators and procurement bodies.
We Say “Do Not Proceed” When Required
Unlike most advisors, we are explicitly hired to stop bad decisions, not justify them.
If the regulatory, reimbursement, or partner risk is misaligned, we say so - clearly and early.
Clients use us as
-
A decision filter
-
A risk buffer
-
A board-level reality check